Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agilent TechnologiesMEX:A 89 Debt-to-EBITDA is 1.68 as of Apr. 2026, which is 8% below its 10-year median of 1.82. GuruFocus rates MEX:A with a GF Score™ of 89/100 and a GF Value™ of MXN2,478.04 (Fairly Valued). The stock has 3 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 58.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Agilent Technologies's Debt-to-EBITDA or its related term are showing as below:
MEX:A'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.45 Med: 1.82 Max: 2.21
Current: 1.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Agilent Technologies was 2.21. The lowest was 1.45. And the median was 1.82.
MEX:A's Debt-to-EBITDA is ranked better than 58.93% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs MEX:A: 1.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Agilent Technologies Debt-to-EBITDA Related Terms
Agilent Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:A vs NTRA, WAT, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Agilent Technologies (MEX:A) has a Debt-to-EBITDA of 1.68 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Agilent Technologies. This is near median its historical median of 1.82. Over the past decade, Agilent Technologies' Debt-to-EBITDA has ranged from 1.45 to 2.21. According to the industry distribution chart, Agilent Technologies ranks #46 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 41.1%.
Is Agilent Technologies' Debt-to-EBITDA too high?
Agilent Technologies' current Debt-to-EBITDA of 1.68 is near median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 2.21. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Agilent Technologies' value of 1.68 is 27.3% below this industry median. Based on the distribution chart, Agilent Technologies ranks #46 out of 112 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Debt-to-EBITDA compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #46 out of 112 companies for Debt-to-EBITDA. This puts Agilent Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 2.31. Agilent Technologies' value of 1.68 is 27.3% below this benchmark. Historically, Agilent Technologies' own Debt-to-EBITDA has ranged from 1.45 to 2.21 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 2.31, Agilent Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agilent Technologies's current Debt-to-EBITDA of 1.68 is 27.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Agilent Technologies. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agilent Technologies's current Debt-to-EBITDA is 1.68, which is near median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MEX:A) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,478.04, compared to a current price of MXN2,350.00 — trading 5.2% below its estimated fair value. The current Debt-to-EBITDA is 1.68, which is near median its 10-year median of 1.82 and 27.3% below the Medical Diagnostics & Research industry median of 2.31. Agilent Technologies' overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Agilent Technologies (MEX:A), the current Debt-to-EBITDA is 1.68 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MEX:A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of MXN2,350.00 is trading 5.2% below its estimated GF Value™ of MXN2,478.04.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MEX:A:
Debt-to-EBITDA: 1.68 (near median its 10-year median of 1.82)
GF Value™: MXN2,478.04 vs. price of MXN2,350.00 (5.2% below fair value)
Industry Position: 27.3% below the Medical Diagnostics & Research median (#46 of 112)
No single metric tells the full story. See the MEX:A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
89GF Score
Get the complete analysis for MEX:A
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:A has been successfully added to your 
